Limitations in the Diagnostic Value of Serum Leucine Aminopeptidase

Hoffman, Elmer; Nachlas, Marvin M.; Gaby, Samuel D.; Abrams, Samuel J.; Seligman, Arnold M.

doi:10.1056/nejm196009152631104

Cited by 24 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase in serum activity of the enzyme during pregnancy and progressive fall in activity in immediate post partum period have b,~_,n reported previously (13,14). Hoffman et al (15) found elevated levels of LAP in benign disease with normal levels in carcinoma. Thus, one cannot correlate the enzyme levelswith neoplastic disease.…”

Section: Resultsmentioning

confidence: 65%

Leucine amino peptidase a better indicator of carcinoma of liver, biliary tract and pancreas

Ghadge

Sirsat

Bhansali

et al. 2001

Indian J Clin Biochem

View full text Add to dashboard Cite

Serum levels of leucine amino peptidase (LAP) was studied along with bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), gamma glutamyl transpeptidase (GGT), alkaline phosphatase(ALP) and the ratio of AST/ALT and GGT/ AST in 26 healthy subjects and 82 patients with hepatobiliary malignancies of which 12 ware with hepatoceUular carcinoma, 12 with liver metastasis, 8 with obstrucUve jaundice, S with carcinoma of gall bladder, (; with carcinoma of pancreas and 7 with periampulisry carcinoma. 24 Of the 62 patients studied had jaundice and 28 were without jaundice.LAP as compared to the other enzymes AST, ALT, GGT, ALP and ASTIALT ratio and GGT/AST ratio showed 100% elevation in obstructive jaundice, carcinoma of gall bladder and pancreas and pedampullary carcinoma, 91.7% elevation in hepatocellular carcinoma and 83.3% elevation in liver metastasis. On comparing the levels of these enzymes in non jaundiced and jaundiced groups, LAP was elevated in both jaundiced and non jaundiced groups in 96.8% and 92.9% cases respectively whereas the other enzymes AST showed increase from (;7.9% to 100%, ALT from 21.4% to 83.3%, GGT from 71.4% to 88.4% and ALP from 82.1% to 100% in non jaundiced and jaundiced groups respectively indicating that LAP rises in hepatic dysfunction due to hepatobiliary malignancy whereas the other liver function enzymes showed increased hepatic dysfunction due to hepatobiliary malignancy with the onset of jaundice thereby indicating that LAP is a better indicator of hepatobiliary malignancy as compared to other enzymes.The quantitative methods used for determination are reliable, accurate, simple, rapid and cost effective and therefore have better application in a clinical setting.

show abstract

Section: Resultsmentioning

confidence: 65%

Leucine amino peptidase a better indicator of carcinoma of liver, biliary tract and pancreas

Ghadge

Sirsat

Bhansali

et al. 2001

Indian J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…Rutenberg et al (11) observed significantly elevated levels of urinary and serum LAP in patients with malignant lymphoma or leukemia had increased urinary activity but normal or slightly elevated serum levels. Hoffman (12) observed serum activity in patients with benign diseases and normal in patients with carcimoma.…”

Section: Resultsmentioning

confidence: 98%

Leucine amino peptidase a better indicator of disseminated malignant disease

Ghadge

Raste

2004

Indian J Clin Biochem

View full text Add to dashboard Cite

Leucine amino peptidase (LAP) activity was studied in serum and urine samples of 25 healthy ambulant subjects, 20 patients with Iocalised and 41 patients with malignant disseminated disease. Serum levels of the enzyme were elevated but not significantly in both Iocalised and disseminated disease whereas the urinary activity of the enzyme was markedly elevated in disseminated disease (p < 0.001) as compared to Iocalised disease. This quantitative method used for determination is reliable, accurate, simple, rapid and cost effective and therefore has better application as an indicator of disseminated disease in a clinical setting.

show abstract

The distribution of naphthylchloracetamidase with implications for the chemotherapy of cancer

Kramer

Seligman

1961

Cancer

View full text Add to dashboard Cite

Limitations in the Diagnostic Value of Serum Leucine Aminopeptidase

Cited by 24 publications

References 14 publications

Leucine amino peptidase a better indicator of carcinoma of liver, biliary tract and pancreas

Leucine amino peptidase a better indicator of carcinoma of liver, biliary tract and pancreas

Leucine amino peptidase a better indicator of disseminated malignant disease

The distribution of naphthylchloracetamidase with implications for the chemotherapy of cancer

Contact Info

Product

Resources

About